ADA: Ecnoglutide Yields Superior, Sustained Reduction in Body Weight
By Elana Gotkine HealthDay Reporter
MONDAY, June 23, 2025 -- For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon like peptide 1 receptor agonist, ecnoglutide, yields a superior and sustained reduction in body weight versus placebo, according to a study published online June 21 in The Lancet Diabetes & Endocrinology to coincide with the annual meeting of the American Diabetes Association, held from June 20 to 23 in Chicago.
Linong Ji, M.D., from the Peking University People's Hospital in Beijing, and colleagues examined the efficacy and safety of once-weekly ecnoglutide versus placebo for the treatment of overweight or obesity. Participants, aged 18 to 75 with overweight or obesity, without diabetes, were randomly assigned to receive subcutaneous ecnoglutide (1.2, 1.8, or 2.4 mg; 166, 166, and 167 participants, respectively) or volume-matched placebo (165 participants), once weekly.
The researchers found that the least-squares mean percentage change in body weight at week 40 was −9.1, −10.9, and −13.2 percent in the ecnoglutide 1.2-, 1.8-, and 2.4-mg groups, respectively, versus 0.1 percent in the placebo group. The proportion of participants who achieved at least a 5 percent reduction in body weight at week 40 was 77, 84, and 87 percent in the ecnoglutide 1.2-, 1.8-, and 2.4-mg groups, respectively, versus 16 percent in the placebo group. Treatment-emergent adverse events were observed in 93 percent in each ecnoglutide dose group and in 84 percent in the placebo group.
"These findings suggest ecnoglutide is a potent therapeutic option for individuals with overweight or obesity, particularly considering its extended dosing range enabling personalized weight management strategies," the authors write.
The study was funded by Hangzhou Sciwind Biosciences, which is developing ecnoglutide.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Minor Complications Up for Black Patients After Weight-Loss Surgery
MONDAY, June 23, 2025 -- Black patients have a higher incidence of minor complications after metabolic and bariatric surgery, according to a study presented at the annual meeting...
Dementia Caregivers Have Modifiable Risk Factors Increasing Their Own Risk
FRIDAY, June 20, 2025 -- Six in 10 dementia caregivers report having at least one modifiable risk factor that could increase their own chances of developing dementia, according to...
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
FRIDAY, June 20, 2025 -- For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.